Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Dyne Therapeutics, Inc. (DYN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $88.72 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $88.72M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $49.38M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $52.78M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $14.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $88.72M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $49.38M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $52.78M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $14.50M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $3.91M 10-Q · filed 2025-07-28 | |
| 2025-03-31 | $6.55M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $61.02M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $149.87M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $178.02M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $133.49M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $38.73M 10-K · filed 2024-03-05 | |
| 2023-09-30 | $15.51M 10-Q · filed 2023-10-30 | |
| 2023-06-30 | $26.46M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $32.23M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $34.88M 10-K · filed 2023-03-02 | |
| 2022-09-30 | $42.54M 10-Q · filed 2022-11-03 | $13.48M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $26.07M 10-Q · filed 2022-05-02 | |
| 2021-12-31 | $36.95M 10-K · filed 2022-03-10 | |
| 2021-09-30 | $57.50M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $87.11M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $59.24M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $90.11M 10-K · filed 2021-03-04 | |
| 2020-09-30 | $84.98M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |